Global Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market, By Treatment (Botulinum toxin A, Surgery, Occupational Therapy, Physical Therapy, Speech Therapy, Others), Diagnosis (Genetic Testing, Blood Tests, Imaging Tests, Others), Route of Administration (Intradermal, Intramuscular, Others), Dosage Form (Powder, Solution), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
CHARGE syndrome is an uncommon condition that affects 0.1-1.2 out of every 10,000 live births. It affects both men and women in equal numbers and has been observed in people of all ethnicities and continents. CHARGE occurs in significantly more cases than those documented in the medical literature. Many cases go untreated or are misdiagnosed, particularly in children who have fewer issues. CHARGE has a modest recurrence risk for parents with one afflicted kid, around 2-3 percent. For an adult with CHARGE, the chance of having an afflicted child again is as high as 50%.
Data Bridge Market Research analyses that the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market was valued at USD 477.8 million in 2021 and is expected to reach USD 674.30 million by 2029, registering a CAGR of 4.40% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Botulinum toxin A, Surgery, Occupational Therapy, Physical Therapy, Speech Therapy, Others), Diagnosis (Genetic Testing, Blood Tests, Imaging Tests, Others), Route of Administration (Intradermal, Intramuscular, Others), Dosage Form (Powder, Solution), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
CHARGE syndrome is a rare genetic condition that impairs your child's growth, coordination, behaviour, development, and intelligence. It also has an impact on the external appearance and interior organs. Surgical correction is possible for several structural problems, including choanal atresia, cleft lip, and heart malformations. Other symptoms, such as feeding difficulties and speech and language impairments, may necessitate years of treatment and other interventions. In a ventilator-dependent new-born with CHARGE syndrome who would have needed a tracheotomy, botulinum toxin A (Botox) is used to control profuse salivary secretions. Affected individuals and their families may benefit from genetic counselling. Symptomatic and supportive treatment is the only other option.
Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Dynamics
Drivers
- Increasing prevalence of CHARGE syndrome
The rising prevalence of CHARGE syndrome is estimated to enhance the market's growth rate. CHARGE syndrome is sporadic (97%) or has an autosomal dominant inheritance pattern. Gonadal mosaicism occurs in 1-2 percent of people. CHARGE syndrome is a complex disorder that manifests itself in a variety of physical and mental health issues that differ from child to child. The senses of hearing, taste, sight, smell, and touch are all affected in children with CHARGE syndrome. CHARGE syndrome is one of the most common causes of birth deafblindness.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, surging number of government initiatives to spread awareness and increasing level of disposable income will result in the expansion of coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market. Along with this, changing lifestyle of people and growing awareness about the early genetic diagnosis will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market growth.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Global Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Scope
The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is segmented on the basis of treatment, diagnosis, route of administration, dosage form, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Botulinum toxin A
- Surgery
- Occupational Therapy
- Physical Therapy
- Speech Therapy
- Others
Diagnosis
- Genetic Testing
- Blood Tests
- Imaging Tests
- Chest X-ray
- Cranial ultrasonography
- Computed tomography (CT) scan
- Magnetic resonance imaging (MRI)
- Abdominal ultrasound
- Skeletal survey
- Echocardiography
- Others
Route of Administration
- Intradermal
- Intramuscular
- Others
Dosage Form
- Powder
- Solution
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Regional Analysis/Insights
The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, dosage form, end-users and distribution channel as referenced above.
The countries covered in the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market because of the well-established healthcare infrastructure and rising awareness among population in this region. Additionally, growing presence of major key players will further propel the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to increasing penetration of novel drugs and rising healthcare expenditure in this region. Also, growing government initiatives will further cushion the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Coloboma, Heart Defects, Atresia Choanae, Growth Retardation, Genital Abnormalities, and Ear Abnormalities (CHARGE) Syndrome Treatment Market Share Analysis
The coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market.
Some of the major players operating in the coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities (CHARGE) syndrome treatment market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- AbbVie Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-